FDA approves Verzenio as the first and only CDK4/6 inhibitor for certain people with HR+HER2-… EP News Bureau Oct 14, 2021 Verzenio phase-III monarchE trial is a randomised (1:1), open-label, two cohort, multi-centre study in adult women and men with…
